Somatostatin analogue in treatment of coexisting glucagonoma and pancreatic pseudocyst: dissociation of responses.
After an acute episode of pancreatitis, a 63-year-old man was found to have a pancreatic glucagonoma. The tumor was resected without evidence of metastases. Three years later he had symptoms of uncontrolled diabetes, no skin lesions, and diarrhea and was found to have a pancreatic pseudocyst and multiple hepatic metastases. Glucagon concentrations were raised but were suppressible by glucose and somatostatin and responded to arginine stimulation. He was treated for 6 months with octreotide (Sandostatin), which reduced his symptoms; the pseudocyst resolved, but liver metastases continued to grow. Although spontaneous resolution of the pseudocyst is possible, this case appears to illustrate differences in sensitivity of endocrine and exocrine tissues to suppression by Sandostatin.
Moattari
A R
AR
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor.
Cho
K
K
Vinik
A I
AI
D007516:Adenoma, Islet Cell / Q000188:drug therapy*; D001120:Arginine / Q000494:pharmacology; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000032:analysis; D004802:Eosinophilia / Q000209:etiology; D005500:Follow-Up Studies; D005934:Glucagon / Q000097:blood; D005935:Glucagonoma / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010181:Pancreatic Cyst / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D010192:Pancreatic Pseudocyst / Q000097:blood / Q000150:complications / Q000188:drug therapy*
D001786:Blood Glucose; D002096:C-Peptide; D005934:Glucagon; D001120:Arginine; D015282:Octreotide